Scholars Central

Short communicationPublished 26 Jul 2016

New HIV protease inhibitors for drug-resistant viruses

Authors: Stefano Rusconi, Ottavia Vigano

Clinical Practice

Volume 3 · Issue 1 · Pages 79

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Several second-generation protease inhibitors have been developed over the last few years. These compounds have been used in preregistrative clinical trials or are currently in various Phases (I, II or III) of their progress towards use in HIV-1-infected patients. All drugs in this category have been designed in order to reach high plasma levels and possibly overcome the issue of cross-resistance among the compounds belonging to this class. Taking into account the rapid occurrence of protease inhibitor cross-resistance, clinicians who are treating patients living with HIV/AIDS will need new active protease inhibitors in the near future. These newly developed compounds will be the subject of our review.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Stefano Rusconi”
  • BylineArticles whose byline prints “Ottavia Vigano”